Dexcom Reports Third Quarter 2021 Financial Results

Go back to Dexcom Reports Third Quarter 2021 Financial Results

DexCom (DXCM) PT Raised to $655 at Jefferies

October 29, 2021 7:43 AM EDT

Jefferies analyst Raj Denhoy raised the price target on DexCom (NASDAQ: DXCM) to $655.00 (from $610.00) while maintaining a Buy rating.

The analyst commented, "XCM posted a $31mn/$0.25 beat on accelerating T2 adoption and OUS momentum which was supplemented by G&A leverage gains.... More